...
首页> 外文期刊>Oncology letters >Mismatch repair hMSH2, hMLH1, hMSH6 and hPMS2 mRNA expression profiles in precancerous and cancerous urothelium
【24h】

Mismatch repair hMSH2, hMLH1, hMSH6 and hPMS2 mRNA expression profiles in precancerous and cancerous urothelium

机译:癌前和癌前尿路上皮中的错配修复hMSH2,hMLH1,hMSH6和hPMS2 mRNA表达谱

获取原文
获取原文并翻译 | 示例
           

摘要

Changes in the expression of the mismatch repair (MMR) genes hMSH2, hMLH1, hMSH6 and hPMS2 reflect dysfunction of the DNA repair system that may allow the malignant transformation of tissue cells. The aim of the present study was to address the mRNA expression profiles of the mismatch DNA repair system in cancerous and precancerous urothelium. This is the first study to quantify MMR mRNA expression by applying quantitative real-time PCR (qPCR) and translate the results to mRNA phenotypic profiles (r, reduced; R, regular or elevated) in bladder tumors [24 urothelial cell carcinomas (UCCs) and I papillary urothelial neoplasm of low malignant potential (PUNLMP)] paired with their adjacent normal tissues (ANTs). Genetic instability analysis was applied at polymorphic sites distal or close to the hMSH2 and hMLH1 locus. Presenting our data, reduced hMSH2, hMSH6 and hPMS2 mRNA expression profiles were observed in cancerous and precancerous urothelia. Significantly, the ANTs of UCCs revealed the highest percentages of reduced hMSH2 (r(2)), hMSH6 (r(6)) and hPMS2 (p(2)) m RNA phenotypes relative to their tumors (P<0.03). In particular, combined r(2)r(6) (P<0.02) presented a greater difference between ANTS of low-grade UCCs vs. their tumors compared with ANTS of high-grade UCCs (P=0.000). Reduced hMLH1 (r(1)) phenotype was not expressed in precancerous or cancerous urothelia. The hMSH6 mRNA was the most changed in UCCs (47.8%). while hMSH2, hMLH1 and hPMS2 showed overexpression (47.8, 35 and 30%, respectively) that was associated with gender and histological tumor grading or staging. Genetic instability was rare in polymorphic regions distal to hMLH1. Our data reveal a previously unrecognized hMSH2 and hMSH6 mRNA combined phenotype (r(2)r(6)) correlated with a precancerous urothelium and show that hMLH1 is transcriptionally activated in precancerous or cancerous urothelium. In the present study, it is demonstrated that reduction of hMSH6 mRNA is a frequent event in bladder tumorigenesis and reflects a common mechanism of suppression with hMSH2, while alterations of hMSH2 or hMLH1 mRNA expression in UCCs does not correlate with the allelic imbalance of polymorphic regions harboring the genes.
机译:错配修复(MMR)基因hMSH2,hMLH1,hMSH6和hPMS2的表达变化反映了DNA修复系统功能异常,可能导致组织细胞恶变。本研究的目的是解决癌症和癌前尿路上皮中错配DNA修复系统的mRNA表达谱。这是第一项通过应用定量实时PCR(qPCR)量化MMR mRNA表达并将结果转化为膀胱肿瘤[24尿路上皮细胞癌(UCC)]中的mRNA表型特征(r,减少,R,正常或升高)的研究。和I低恶性乳头状尿路上皮肿瘤(PUNLMP)]与相邻的正常组织(ANTs)配对。遗传不稳定性分析应用于hMSH2和hMLH1基因座远端或附近的多态性位点。提供我们的数据,在癌性和癌前性尿路上皮中观察到hMSH2,hMSH6和hPMS2 mRNA表达降低。值得注意的是,相对于肿瘤,UCCs的ANTs显示出降低的hMSH2(r(2)),hMSH6(r(6))和hPMS2(p(2))m RNA表型的百分比最高(P <0.03)。特别地,与高级UCC的ANTS相比,组合r(2)r(6)(P <0.02)在低级UCC的ANTS与其肿瘤之间呈现出更大的差异(P = 0.000)。减少的hMLH1(r(1))表型未在癌前或癌性尿路上皮中表达。 hMSH6 mRNA在UCC中变化最大(47.8%)。而hMSH2,hMLH1和hPMS2显示过表达(分别为47.8、35和30%),这与性别和组织学肿瘤分级或分期有关。遗传不稳定性在hMLH1远端的多态性区域很少见。我们的数据揭示了以前无法识别的hMSH2和hMSH6 mRNA组合表型(r(2)r(6))与癌前尿路上皮相关,并显示hMLH1在癌前尿路上皮或癌性尿路上皮中被转录激活。在本研究中,已证明hMSH6 mRNA的减少是膀胱肿瘤发生中的常见事件,并反映了hMSH2抑制的常见机制,而UCC中hMSH2或hMLH1 mRNA表达的改变与多态性区域的等位基因失衡无关。携带基因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号